Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia

Schizophrenia Bulletin

Volumn 38, Issue 4, 2012, Pages 845-853

  Olfson, Mark ^a,b   Gerhard, Tobias ^c,d   Huang, Cecilia ^c   Lieberman, Jeffrey A ^a,b   Bobo, William V ^e   Crystal, Stephen ^c  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antipsychotics; child psychiatry; comparative effectiveness; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

ADOLESCENT; ADVERSE OUTCOME; ANXIETY DISORDER; ARTICLE; AUTISM; CHILD; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DISRUPTIVE BEHAVIOR; DRUG WITHDRAWAL; FEMALE; GROUP THERAPY; HISPANIC; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; JUVENILE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL HOSPITAL; MENTAL PATIENT; MONOTHERAPY; OUTPATIENT CARE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCHOOL CHILD; COMPARATIVE STUDY; PATIENT COMPLIANCE; PSYCHOSIS; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; DIBENZOTHIAZEPINES; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MEDICATION ADHERENCE; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 84871891828     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbq172     Document Type: Article

References (47)

1. Frazier JA, McClellan J, Findling RL, et al. Treatment of early-onset Schizophrenai spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2007;436:979-988. (Pubitemid 47220682)
2. McClellan J, McCurry C, Speltz ML, Jones K. Symptom factors in early-onset psychotic disorders. J Am Acad Child Adolesc Psychiatry. 2002;41:791-798. (Pubitemid 38338094)
3. Fleischhaker C, Shulz E, Tepper K, Martin M. Long-term course of adolescent Schizophrenai. Schizophr Bull. 2005;31:769-780.
4. Ropke B, Eggers C. Early-onset Schizophrenai: a 15-year follow-up. Eur Child Adolesc Psychiatry. 2005;14:341-350.
5. Fagerlund B, Pagsberg AK, Hemmingsen RP. Cognitive deficits and levels of IQ in adolescent onset Schizophrenai and other psychotic disorders. Schizophr Res. 2006;85:30-39. (Pubitemid 43947521)
6. Alaghband-Rad J, McKenna K, Gordon C, et al. Child-onset Schizophrenai: the severity of premorbid course. J Am Acad Child Adolesc Psychiatry. 1995;34:1273-1283.
7. Eggers C, Bunk D. The long-term course of childhood-onset Schizophrenai: a 42-year followup. Schizophr Bull. 1997;23:105-117. (Pubitemid 27087911)
8. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with Schizophrenai: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60-70.
9. Robb AS, Findling RL, Nyilas M, et al. Efficacy of Aripiprazole in the Treatment of Adolescents With Schizophrenai. in 2007 Annual Meeting New Research Program and Abstracts. Arlington, VA, American Psychiatric Association, 2007:319-320.
10. Haas M, Unis AS, Copenhaver M, et al. Efficacy and Safety of Risperidone in Adolescents With Schizophrenai. in 2007 Annual Meeting New Research Program and Abstracts. Arlington, VA, American Psychiatric Association, 2007:221-222.
11. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset Schizophrenai and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenai Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-1431.
12. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic Schizophrenai. N Engl J Med. 2005;353:1209-1223. (Pubitemid 41345943)
13. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenai trial. Schizophr Bull. 2003;29:33-43. (Pubitemid 36871055)
14. Kreyenbuhl J, Nossel I, Dixon L. Disengagement from mental health treatment among individuals with Schizophrenai and strategies for facilitating connections to care: a review of the literature. Schizophr Bull. 2009;35:696-703.
15. Olfson M, Mojtabai R, Sampson NA, et al. Dropout from outpatient mental health care in the United States. Psychiatr Serv. 2009;60:898-907.
16. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with Schizophrenai: medication and patient factors. Schizophr Bull. 2004;30:255-264. (Pubitemid 38828533)
17. Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol. 2003;23:389-399. (Pubitemid 36951182)
18. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with Schizophrenai. Am J Psychiatry. 2004;161:692-699. (Pubitemid 38445514)
19. Remschmidt H. Schizophrenai in children and adolescents. In: Babaschewski T, Rohde LA, eds. Biological child psychiatry: recent trends and developments.Vol 24: Adv Biol Psychiatry. Basel, Switzerland: S. Karger AG; 2008:118-127.
20. Kaiser Commission on Medicaid and the Uninsured.Health coverage of children: The role of Medicaid and SCHIP. http://www.kff.org/uninsured/upload/ 7698-02.pdf. Accessed November 11, 2010.
21. US Bureau of the Census. Annual Estimates of the Resident Population by Sex and Selected Age Groups for the United States: April 1, 2000 to July 1, 2009 (NC-EST2009-02). http://www.census.gov/popest/national/asrh/NC-EST2009/ NCEST2009-02.csv. Accessed November 11, 2010.
22. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994;47:731-737. (Pubitemid 24236255)
23. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920. (Pubitemid 37323253)
24. Olfson M, Marcus SC, Doshi JA. Continuity of care after inpatient discharge of Schizophrenai patients. J Clin Psychiatry. 2010;71:831-838.
25. Armenteros JL, Davis M. Antipsycotics in early onset Schizophrenai: systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2006;15:141-148.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
27. Crystal S, Akincigil A, Bilder S, Walkup JT. Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Med Care. 2007;45(Suppl 2):S58-S65.
28. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotics. Arch Gen Psychiatry. 2006;63:679-685. (Pubitemid 43848299)
29. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk or rehospitalization among California Medicaid patients with Schizophrenai. Psychiatr Serv. 2004;55:886-891. (Pubitemid 39025215)
30. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with Schizophrenai at increased risk for admission. Med Care. 2002;40:630-639.
31. Harman JS, Childs GE, Kelleher KJ. Mental health care utilization and expenditures by children in foster care. Arch Pediatr Adolesc Med. 2000;154:1114-1117.
32. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805-811. (Pubitemid 32577440)
33. Lacro JP, Dunn LB, Dolder CR, Leckban SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with Schizophrenai: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909. (Pubitemid 35231730)
34. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand. 1999;100:167-175. (Pubitemid 29409082)
35. Gianfrancesco F, Hwang RH, Pesa J, Rajagopalan K. Hospitalisation risks in the treatment of Schizophrenai in a Medicaid population: comparison of antipsychotic medications. Int J Clin Pract. 2006;60:1419-1424. (Pubitemid 44560341)
36. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302: 1765-1773.
37. Chartbook: Medicaid Pharmaceutical Benefit Use and Reimbursement in 2003. http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/downloads/Pharmacy-RX- Chartbook-2003.pdf. Accessed June 25, 2009.
38. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care. 2010;48:4-9.
39. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv. 2008;59:540-546.
40. Koyanagi C, Forquer S, Alfano E. Medicaid policies to contain psychiatric drug costs. Health Aff. 2005;24:536-544. (Pubitemid 40528973)
41. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset Schizophrenai: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63:524-529. (Pubitemid 351220784)
42. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset Schizophrenai: a double-blind, randomized, clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63:721-730.
43. Dixon LB, Dickerson F, Bellack AS, et al. Schizophrenai Patient Outcomes Research Team (PORT). Schizophr Bull. 2010;36:48-70.
44. Lurie N, Popkin M, Dysken M, Moscovice I, Finch M. Accuracy of diagnoses of Schizophrenai in Medicaid claims. Hosp Community Psychiatry. 1992;43:69-71.
45. Walkup JT, Boyer CA, Kellermann SL. Reliability of Medicaid claims files for use in psychiatric diagnoses and service delivery. Adm Policy Ment Health. 2000;27:129-139. (Pubitemid 30205260)
46. Elkis H. Treatment-resistant Schizophrenai. Psychiatr Clin North Am. 2007;30:511-533.
47. Kumra S, Frazier JA, Jacobsen LK, et al. Childhoodonset Schizophrenai: a double-blind randomized clozapinehaloperidol comparison. Arch Gen Psychiatry. 1996;53: 1090-1097.